Takeda Takes PvP Biologics

28.02.2020 - Japanese drugmaker Takeda Pharmaceutical has acquired PvP Biologics, following the conclusion of a Phase 1 proof-of-mechanism study of TAK-062 (Kuma062), an investigational...